Orthobiologics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Orthobiologics Market is segmented by Product (Viscosupplementation Products, Demineralized Bone Matrices, Synthetic Orthobiologics, Bone Morphogenic Protein, Allografts, and Others (Plasma-rich Protein, and Bone Marrow Aspirate Concentrate)), Application, (Osteoarthritis and Degenerative Arthritis, Spinal Fusion, Soft-tissue Injuries, and Others (Fracture Recovery, and Maxillofacial and Dental Applications)), End User (Hospitals, Orthopedic Clinics, and Ambulatory Care Centers, Academic and Research Institutes, and Dental Clinics and Facilities), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America).

Orthobiologics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Orthobiologics Market Size

Orthobiologics Market Summary
Study Period 2021 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 6.68 Billion
Market Size (2030) USD 9.06 Billion
CAGR (2025 - 2030) 6.30 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Orthobiologics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Orthobiologics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Orthobiologics Market Analysis

The Orthobiologics Market size is estimated at USD 6.68 billion in 2025, and is expected to reach USD 9.06 billion by 2030, at a CAGR of 6.3% during the forecast period (2025-2030).

The COVID-19 outbreak is an unprecedented health concern and has significantly impacted the orthobiologics market globally. According to a 2021 update by the National Safety Council (NSC) in America, the Consumer Product Safety Commission (CPSC) reported that during the first seven months of the COVID-19 pandemic, visits to emergency departments for consumer product-related injuries decreased by 24%. The highest decrease in injuries was sports-related injuries associated with track and field. Hockey, soccer, baseball, football, and basketball witnessed a more than 60% reduction from March through September 2020. Thus, the COVID-19-imposed lockdown impacted the orthobiologics market significantly. However, with a better screening process, the market is now opening up, which is increasing growth. For instance, in April 2022, an article published in the Europe PMC stated that after a year of maintaining 'non-COVID' hospital status for elective surgery, restrictions began to ease as the COVID-19 positivity rate dropped to 1.2% in Nassau County, New York on 1 May 2021. On 3 May 2021, on-site pre-surgical testing (PST) appointments resumed. Thus, the market is expected to grow in the future.

The major factors driving the growth of the orthobiologics market are increased incidence of sports injury, road accidents, osteoarthritis, and increasing adoption of minimally invasive surgeries. As per the 2020 statistics by the United Kingdom National Health Service, tennis elbow is a common condition affecting about 1-3% of the population, indicating about four to seven cases per 1000 every year. The high incidences of sports injuries boost the demand for orthobiologics for effective treatment, thus fueling the market.

The global increase in the number of geriatrics and obese people is likely to lead to consequences like greater incidences of osteoarthritis. Consequently, the geriatric population and population with obesity are at higher risk of musculoskeletal disorders. According to the World Health Organization (WHO), approximately 1.71 billion people had musculoskeletal conditions worldwide in 2021. Among musculoskeletal disorders, low back pain causes the highest burden, with a prevalence of 568 million people. According to the report published by Versus Arthritis stated that over 20 million people in the United Kingdom (around a third of the population) live with a musculoskeletal (MSK) condition, such as arthritis and low back pain. Overall, 21% of the UK population lived with illness and disability (YLD) and was associated with MSK conditions. Low back, neck pain, and osteoarthritis are the most common causes of pain and disability. The source stated that over 430,000 people have rheumatoid arthritis, around 12,000 children have juvenile idiopathic arthritis, 220,000 people have axial spondylarthritis, and around 100,000 people have psoriatic arthritis. Nearly 8.5 million people have osteoarthritis, 10 million have back pain, 1.7 to 2.8 million people have fibromyalgia, 3 million have osteoporosis, and around 500,000 fragility fractures occur yearly. Therefore, with the increase in musculoskeletal injuries, the demand for orthobiologics is expected to increase, driving the market growth.

Moreover, launching new products and strategic initiatives adopted by key market players is expected to boost the studied market growth. For instance, in April 2021, Ventris Medical launched Allocell AF, a next-generation osteoinductive fiber allograft. It enhances intra-operative handling and increases biological responsiveness at the defect site.

Thus, due to the factors such as increased incidence of injury, obese people, and product launches, the studied market is expected to grow significantly during the study period. However, the high cost of biologic-based treatments and preference for other alternatives is expected to hinder the market growth.

Orthobiologics Industry Overview

The orthobiologics market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and high prevalence of diseases, a few other smaller players are expected to enter the market in the future. Some of the market's major players are Sanofi, Stryker, Zimmer Biomet, Seaspine Holdings Corporation, and Medtronic, among others.

Orthobiologics Market Leaders

  1. Sanofi SA

  2. Stryker Corporation

  3. Zimmer Biomet

  4. Seaspine Holdings Corporation

  5. Medtronic PLC

  6. *Disclaimer: Major Players sorted in no particular order
4.png
Need More Details on Market Players and Competiters?
Download PDF

Orthobiologics Market News

  • March 2022: SeaSpine launched the NorthStar cervical facet fusion and Flash navigation lumbar facet fusion orthobiologic systems to streamline reproducible procedural workflow while maximizing the area for fusion with OsteoStrand DBM fibers contained within the facet joint.
  • January 2022: Bone Solutions Inc. launched Mg OSTEOINJECT, the first injectable bone void filler in the United States to incorporate magnesium - a critical component for bone health and development. This product could promote bone repair and regeneration within insufficiency and micro fractures.

Orthobiologics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidences of Sports Injuries and Road Accidents
    • 4.2.2 Increasing Incidence of Osteoarthritis
    • 4.2.3 Increasing Geriatric and Obese Population
    • 4.2.4 Increasing Patient Preference for Minimally Invasive Procedures
  • 4.3 Market Restraints
    • 4.3.1 High Costs Associated with Orthobiologic-based Treatments
    • 4.3.2 Preference for Alternative Treatment Options
  • 4.4 Porter Five Forces
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By Products
    • 5.1.1 Viscosupplementation Products
    • 5.1.2 Demineralized Bone Matrices
    • 5.1.3 Synthetic Orthobiologics
    • 5.1.4 Bone Morphogenic Protein
    • 5.1.5 Allografts
    • 5.1.6 Other Products (Plasma-rich Protein and Bone Marrow Aspirate Concentrate)
  • 5.2 By Application
    • 5.2.1 Osteoarthritis and Degenerative Arthritis
    • 5.2.2 Spinal Fusion
    • 5.2.3 Soft-tissue Injuries
    • 5.2.4 Other Applications (Fracture Recovery and Maxillofacial and Dental Applications)
  • 5.3 By End User
    • 5.3.1 Hospitals, Orthopedic Clinics, and Ambulatory Care Centers
    • 5.3.2 Research and Academic Institutes
    • 5.3.3 Dental Clinics and Facilities
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Arthrex Inc.
    • 6.1.2 Sanofi
    • 6.1.3 DePuy Synthes (A Subsidiary of Johnson & Johnson)
    • 6.1.4 Globus Medical Inc.
    • 6.1.5 Terumo Corporation
    • 6.1.6 Stryker Corporation
    • 6.1.7 Zimmer Biomet
    • 6.1.8 Medtronic PLC
    • 6.1.9 NuVasive Inc.
    • 6.1.10 Integra Lifesciences
    • 6.1.11 Bone Support
    • 6.1.12 Seaspine Holdings Corporation
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Orthobiologics Industry Segmentation

As per the report's scope, orthobiologics are used by orthopedic surgeons to help injuries heal more quickly. They quicken the healing of broken bones and injured muscles, tendons, and ligaments. These products are made from substances that are naturally found in our bodies. The Orthobiologics Market is Segmented by Product (Viscosupplementation Products, Demineralized Bone Matrices, Synthetic Orthobiologics, Bone Morphogenic Protein, Allografts, and Others (Plasma-rich Protein, and Bone Marrow Aspirate Concentrate)), Application, (Osteoarthritis and Degenerative Arthritis, Spinal Fusion, Soft-tissue Injuries, and Others (Fracture Recovery, and Maxillofacial and Dental Applications)), End User (Hospitals, Orthopedic Clinics, and Ambulatory Care Centers, Academic and Research Institutes, and Dental Clinics and Facilities), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.

By Products Viscosupplementation Products
Demineralized Bone Matrices
Synthetic Orthobiologics
Bone Morphogenic Protein
Allografts
Other Products (Plasma-rich Protein and Bone Marrow Aspirate Concentrate)
By Application Osteoarthritis and Degenerative Arthritis
Spinal Fusion
Soft-tissue Injuries
Other Applications (Fracture Recovery and Maxillofacial and Dental Applications)
By End User Hospitals, Orthopedic Clinics, and Ambulatory Care Centers
Research and Academic Institutes
Dental Clinics and Facilities
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Orthobiologics Market Research FAQs

How big is the Orthobiologics Market?

The Orthobiologics Market size is expected to reach USD 6.68 billion in 2025 and grow at a CAGR of 6.30% to reach USD 9.06 billion by 2030.

What is the current Orthobiologics Market size?

In 2025, the Orthobiologics Market size is expected to reach USD 6.68 billion.

Who are the key players in Orthobiologics Market?

Sanofi SA, Stryker Corporation, Zimmer Biomet, Seaspine Holdings Corporation and Medtronic PLC are the major companies operating in the Orthobiologics Market.

Which is the fastest growing region in Orthobiologics Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Orthobiologics Market?

In 2025, the North America accounts for the largest market share in Orthobiologics Market.

What years does this Orthobiologics Market cover, and what was the market size in 2024?

In 2024, the Orthobiologics Market size was estimated at USD 6.26 billion. The report covers the Orthobiologics Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Orthobiologics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Orthobiologics Industry Report

Statistics for the 2025 Orthobiologics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Orthobiologics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.